|
KMID : 1142120200220010108
|
|
Journal of Stroke
2020 Volume.22 No. 1 p.108 ~ p.118
|
|
|
Changes in High-Density Lipoprotein Cholesterol and Risks of Cardiovascular Events: A Post Hoc Analysis from the PICASSO Trial
|
|
Lee Eun-Jae
Kwon Sun-U.
Park Jong-Ho
Kim Yong-Jae
Hong Keun-Sik
Yu Sung-Wook
Hwang Yang-Ha
Lee Ji-Sung
Lee June-Young
Rha Joung-Ho
Heo Sung-Hyuk
Ahn Sung-Hwan
Seo Woo-Keun
Park Jong-Moo
Lee Ju-Hun
Kwon Jee-Hyun
Sohn Sung-Il
Jung Jin-Man
Kim Hahn-Young
Kim Eung-Gyu
Kim Sung-Hun
Cha Jae-Kwan
Park Man-Seok
Nam Hyo-Suk
Kang Dong-Wha
|
|
|
Abstract
|
|
|
Background and purpose: Whether pharmacologically altered high-density lipoprotein cholesterol (HDL-C) affects the risk of cardiovascular events is unknown. Recently, we have reported the Prevention of Cardiovascular Events in Asian Patients with Ischaemic Stroke at High Risk of Cerebral Haemorrhage (PICASSO) trial that demonstrated the non-inferiority of cilostazol to aspirin and superiority of probucol to non-probucol for cardiovascular prevention in ischemic stroke patients (clinicaltrials.gov: NCT01013532). We aimed to determine whether on-treatment HDL-C changes by cilostazol and probucol influence the treatment effect of each study medication during the PICASSO study.
Methods: Of the 1,534 randomized patients, 1,373 (89.5%) with baseline cholesterol parameters were analyzed. Efficacy endpoint was the composite of stroke, myocardial infarction, and cardiovascular death. Cox proportional hazards regression analysis examined an interaction between the treatment effect and changes in HDL-C levels from randomization to 1 month for each study arm.
Results: One-month post-randomization mean HDL-C level was significantly higher in the cilostazol group than in the aspirin group (1.08 mmol/L vs. 1.00 mmol/L, P<0.001). The mean HDL-C level was significantly lower in the probucol group than in the non-probucol group (0.86 mmol/L vs. 1.22 mmol/L, P<0.001). These trends persisted throughout the study. In both study arms, no significant interaction was observed between HDL-C changes and the assigned treatment regarding the risk of the efficacy endpoint.
Conclusions: Despite significant HDL-C changes, the effects of cilostazol and probucol treatment on the risk of cardiovascular events were insignificant. Pharmacologically altered HDL-C levels may not be reliable prognostic markers for cardiovascular risk.
|
|
|
KEYWORD
|
|
|
Cholesterol, HDL, Secondary prevention, Cilostazol, Probucol, Cholesterol ester transfer proteins
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|